This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/AHFS/
n28http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/mesh/concept/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00142/identifier/chemspider/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00142/identifier/chebi/
n13http://bio2rdf.org/drugbank:
n27http://linked.opendata.cz/resource/drugbank/drug/DB00142/identifier/wikipedia/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00142/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00142/identifier/kegg-compound/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00142/identifier/bindingdb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00142/identifier/pdb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00142/identifier/pubchem-compound/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00142/identifier/pubchem-substance/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00142/identifier/kegg-drug/
n4http://linked.opendata.cz/resource/drugbank/property/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00142/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00142/identifier/iuphar/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00142/identifier/guide-to-pharmacology/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00142
rdf:type
n3:Drug
n3:description
A peptide that is a homopolymer of glutamic acid. [PubChem]
n3:generalReferences
# Smith QR: Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr. 2000 Apr;130(4S Suppl):1016S-22S. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10736373 # Okumoto S, Looger LL, Micheva KD, Reimer RJ, Smith SJ, Frommer WB: Detection of glutamate release from neurons by genetically encoded surface-displayed FRET nanosensors. Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8740-5. Epub 2005 Jun 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15939876 # Reeds PJ, Burrin DG, Stoll B, Jahoor F: Intestinal glutamate metabolism. J Nutr. 2000 Apr;130(4S Suppl):978S-82S. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10736365 # Corrie JE, DeSantis A, Katayama Y, Khodakhah K, Messenger JB, Ogden DC, Trentham DR: Postsynaptic activation at the squid giant synapse by photolytic release of L-glutamate from a 'caged' L-glutamate. J Physiol. 1993 Jun;465:1-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7901400 # Augustin H, Grosjean Y, Chen K, Sheng Q, Featherstone DE: Nonvesicular release of glutamate by glial xCT transporters suppresses glutamate receptor clustering in vivo. J Neurosci. 2007 Jan 3;27(1):111-23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17202478
n3:group
nutraceutical
n3:indication
Considered to be nature's "Brain food" by improving mental capacities; helps speed the healing of ulcers; gives a "lift" from fatigue; helps control alcoholism, schizophrenia and the craving for sugar.
owl:sameAs
n6:DB00142 n13:DB00142
dcterms:title
L-Glutamic Acid
adms:identifier
n12:46505816 n14:GLU n15:33032 n16:C00025 n19:D00007 n20:1369 n21:1369 n22:30572 n23:DB00142 n24:17657 n25:16015 n26:PA449776 n27:L-Glutamic_Acid
n3:mechanismOfAction
Glutamate activates both ionotropic and metabotropic glutamate receptors. The ionotropic ones being non-NMDA (AMPA and kainate) and NMDA receptors. Free glutamic acid cannot cross the blood-brain barrier in appreciable quantities; instead it is converted into L-glutamine, which the brain uses for fuel and protein synthesis. It is conjectured that glutamate is involved in cognitive functions like learning and memory in the brain, though excessive amounts may cause neuronal damage associated in diseases like amyotrophic lateral sclerosis, lathyrism, and Alzheimer's disease. Also, the drug phencyclidine (more commonly known as PCP) antagonizes glutamate at the NMDA receptor, causing behavior reminiscent of schizophrenia. Glutamate in action is extremely difficult to study due to its transient nature.
n3:packager
n28:271B4AA6-363D-11E5-9242-09173F13E4C5
n3:synonym
L-Glutaminic acid (S)-2-Aminopentanedioic acid Glutamic acid Glu (S)-Glutamic acid L-Glutamate (2S)-2-Aminopentanedioic acid
n3:toxicity
Glutamate causes neuronal damage and eventual cell death, particularly when NMDA receptors are activated, High dosages of glutamic acid may include symptoms such as headaches and neurological problems.
n9:hasAHFSCode
n10:40-04-00
n3:synthesisReference
Nobuharu Tujimoto, Yoshimi Kikuchi, Osamu Kurahashi, Yoshiko Kawahara, "Mutant Escherichia coli capable of enhanced L-glutamic acid production." U.S. Patent US5393671, issued August, 1960.
n17:hasConcept
n18:M0028010
n3:IUPAC-Name
n4:271B4AAC-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4AB2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4AB1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4AAE-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4AAF-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4AB0-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4AC2-363D-11E5-9242-09173F13E4C5 n4:271B4AAA-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4AAB-363D-11E5-9242-09173F13E4C5 n4:271B4AA8-363D-11E5-9242-09173F13E4C5 n4:271B4AC4-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4AA9-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4AC5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4AB8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4AB9-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4AB3-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4AB4-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4AB6-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4AB5-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4AB7-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorbed from the lumen of the small intestine into the enterocytes.Absorption is efficient and occurs by an active transport mechanism.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
56-86-0
n3:category
n3:containedIn
n8:271B4AA7-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4ABE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4AC0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4AC1-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4AC3-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4ABD-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4ABC-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4ABF-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4AAD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4ABA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4ABB-363D-11E5-9242-09173F13E4C5